Physician profile
Scott David
NPI 1982600888
$3,865.81
in general payments reported to CMS, 2019-2025
15 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.42 · 2021: $117 · 2022: $2,519 · 2023: $538 · 2024: $302 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $2,106.42 | 2019-2022 | |
| Astellas Pharma US INC | $316.50 | 2022-2024 | Myrbetriq, Veozah |
| Endo USA, INC. | $239.15 | 2024-2025 | Aveed, Xiaflex, Edex |
| Antares Pharma, INC. | $224.93 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Procept Biorobotics Corporation | $218.96 | 2021-2023 | Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $189.63 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $122.87 | 2022 | |
| Pfizer INC. | $113.81 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $111.99 | 2022-2024 | Aveed, Xiaflex, Edex |
| Merck Sharp & Dohme LLC | $88.35 | 2022-2023 | Lynparza, Keytruda, Welireg |
| Abbvie INC. | $47.78 | 2022 | |
| Dendreon Pharmaceuticals LLC | $43.95 | 2025 | Provenge |
| Halozyme INC | $21.44 | 2023 | |
| Acerus Pharmaceuticals Corporation | $20.03 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.